Results 21 to 30 of about 5,356 (175)
Current Issues in Molecular Biology, 2023 The appropriate dosage of edaravone—a radioprotective agent—and its effect on tumors are unknown. This study evaluated the effects of edaravone on intestinal injuries and tumors in mice induced by whole body X-ray irradiation.
Terufumi Kawamoto, Keisuke Sasai
doaj +1 more source
Application of a free radical scavenger edaravone in patients with hemorrhagic stroke
Infusion & Chemotherapy, 2021 BACKGROUND. The free radical scavenger edaravone helps to reduce the area of ischemic injury and improve the longterm effects of stroke, and is therefore widely used in the treatment of ischemic stroke.
O.A. Halushko
doaj +1 more source
Safety of Intravenous Edaravone in Clinical Practice. [PDF]
Muscle NerveABSTRACT This article summarizes the post‐marketing pharmacovigilance safety data of intravenous (IV) edaravone during the 1‐ and 3‐year periods following its launch for amyotrophic lateral sclerosis (ALS) in the United States. The most frequently reported adverse events (AEs) and serious AEs (SAEs) included those consistent with ALS ...
Genge A, Apple S.
europepmc +4 more sources
Formulary Drug Review: Edaravone [PDF]
Hospital Pharmacy, 2017 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Zaynah K, Ali, Danial E, Baker
openaire +2 more sources
Turkish Journal of Vascular Surgery, 2023 Aim: Lower limb ischemia/reperfusion leads to distant organ dysfunction, notably affecting the lungs, resulting in respiratory failure and significant morbidity and mortality.
Mehmet Ceber +4 more
doaj +1 more source
Pharmaceuticals, 2021 Reports on the long-term survival effect of edaravone, which was approved for the treatment of amyotrophic lateral sclerosis (ALS) in 2015 in Japan, are rare.
Hideki Houzen +5 more
doaj +1 more source
Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons
BMC Neuroscience, 2008 Background Parkinson's disease (PD) is a neurological disorder characterized by the degeneration of nigrostriatal dopaminergic systems. Free radicals induced by oxidative stress are involved in the mechanisms of cell death in PD. This study clarifies the
Wang Feifei +15 more
doaj +1 more source
Solid Lipid Nanoparticles Loaded with Edaravone for Inner Ear Protection After Noise Exposure
Chinese Medical Journal, 2015 Background: Antioxidants and the duration of treatment after noise exposure on hearing recovery are important. We investigated the protective effects of an antioxidant substance, edaravone, and its slow-release dosage form, edaravone solid lipid ...
Gang Gao +4 more
doaj +1 more source
Edaravone for acute ischaemic stroke
Cochrane Database of Systematic Reviews, 2011 Neuroprotection is a promising therapeutic strategy for the treatment of acute ischaemic stroke. Edaravone is a neuroprotective agent that has been widely used in China, and several studies have suggested that it may be beneficial in acute ischaemic stroke.To assess the efficacy and safety of edaravone for acute ischaemic stroke.We searched the ...
Feng, Shejun +7 more
openaire +4 more sources
Efficacy of Edaravone in Cardioembolic Stroke
Internal Medicine, 2006 We investigated the efficacy of edaravone in patients with cardioembolic stroke.Cardioembolic stroke patients were treated with drip intravenous infusion of edaravone (ED group, n=141) for 7 days, and were retrospectively compared with a historical-controlled cohort of similar patients (control group, n=114).Early improvement (between day 0 and day 10),
Inatomi, Yuichiro +6 more
openaire +3 more sources